Yi Chen
Taiyuan, 030001, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: PDZK1 inhibits MRP2-mediated oxaliplatin chemosensitivity in hepatocellular carcinoma.
Journal: Scientific reports
Published: March 25, 2026
Global research trends and emerging frontiers of nanozymes in cancer therapy based on bibliometric and knowledge mapping analysis from 2001 to 2025.
Journal: Discover nano
Published: January 04, 2026
The Prognostic Nutritional Index (PNI) as a Biomarker for Predicting Survival in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization and Lenvatinib, With or Without Programmed Death-1(PD-1) Inhibitors.
Journal: Cardiovascular and interventional radiology
Published: October 07, 2025
Comparison of Milan versus up-to-seven criteria for liver resection in hepatocellular carcinoma: a multi-center study on risk factors and long-term outcomes.
Journal: Surgical endoscopy
Published: July 27, 2025
PDZK1 inhibits MRP2-mediated oxaliplatin chemosensitivity in hepatocellular carcinoma.
Journal: Scientific reports
Published: December 08, 2024
Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study.
Journal: Frontiers in immunology
Published: June 15, 2024
Color-coded parametric imaging support display of vessel hemorrhage-an in vitro experiment and clinical validation study.
Journal: Frontiers in cardiovascular medicine
Published: February 22, 2024
The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Journal: Frontiers in oncology
Published: September 26, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026